Month: May 2025

Artif Organs. 2025 Apr 11. doi: 10.1111/aor.15010. Online ahead of print.

ABSTRACT

BACKGROUND: Glutaraldehyde (GA) generates cross-links between cardiovascular xenografts to obtain tissue stability and attenuate antigenicity. However, the long-term durability of GA-fixed cardiovascular xenografts treated with previous anticalcification strategies has remained a challenge because tissue phospholipids, free aldehyde groups of GA, and residual antigenicity contribute to calcification. This study aimed to assess the safety, efficacy, and clinical performance of a bovine pericardial scaffold treated with our novel anticalcification protocols (Periborn) in patients with cardiovascular diseases.

METHODS: Bovine pericardia were decellularized with 0.25% sodium dodecyl sulfate, 0.5% Triton X-100, and treated with a space-filler with polyethylene glycol. These tissues were cross-linked with 0.5% GA in a 75% ethanol +5% octanol organic solvent and treated with glycine for detoxification to produce Periborn. Between July 2015 and April 2022, 451 Periborn patches were implanted in 352 cases for cardiovascular surgeries.

RESULTS: The mean age at the time of surgery was 22.74 ± 20.09 years (13 days-89.5 years), follow-up duration was 4.25 ± 2.56 years (17 days-8.6 years), and no patch-related mortalities were observed. Five patients were reoperated owing to patch-related complications including decreased mobility, erosion, pseudoaneurysm, and calcification, and the overall probability of freedom from Periborn-related reoperation was 99.4% ± 0.4% at 1 year, 98.6% ± 0.7% at 5 years, and 95.4% ± 3.2% at 9 years.

CONCLUSIONS: This retrospective study demonstrates the safety and efficacy of the tissue-engineered Periborn bovine pericardial scaffold for the surgical repair of various cardiovascular diseases. The excellent durability and hemodynamic performance of Periborn make our novel anti-calcification protocol attractive and may require long-term follow-up to confirm durability and further research.

PMID:40213904 | DOI:10.1111/aor.15010

Dan Med J. 2025 Jan 21;72(2):A08240522. doi: 10.61409/A08240522.

ABSTRACT

INTRODUCTION: Immediate, implant-based breast reconstruction has become increasingly popular as a single-stage procedure with prepectoral placement of the implant following the introduction of biologic matrices. Only a few studies have described the use of bovine pericardium matrixTutomesh, a xenograft derived from bovine pericardium – and the use of laser-assisted indocyanine green angiography (ICG-A) to assess skin flap perfusion.

METHODS: All patients who underwent a mastectomy followed by immediate reconstruction using prepectoral direct-to-implant with bovine pericardium from July 2019 to June 2021 were included. Complications were registered using the Clavien-Dindo classification. Postsurgical complications were analysed with multivariate logistic regression and feature selection.

RESULTS: A total of 81 prepectoral breast reconstructions were performed in 56 patients. The overall complication rate was 38.2%, and 14.3% required reoperation. Implant loss occurred in 3.7%. Multivariate logistic regression analysis demonstrated a statistically significant association between the risk of skin necrosis and previous breast surgery (p = 0.020) along with an increasing risk of implant rotation with increasing age (p = 0.010). The median follow-up was 9.9 months, and 11.1% of the breast reconstructions required postsurgical aesthetic correction.

CONCLUSIONS: Bovine pericardium may be used in prepectoral breast reconstruction with a good outcome. Careful patient selection is crucial, and ICG-A is helpful in reducing the risk of post-surgical complications.

FUNDING: None.

TRIAL REGISTRATION: Not relevant.

PMID:40125960 | DOI:10.61409/A08240522

Artif Organs. 2025 Apr 11. doi: 10.1111/aor.15010. Online ahead of print.

ABSTRACT

BACKGROUND: Glutaraldehyde (GA) generates cross-links between cardiovascular xenografts to obtain tissue stability and attenuate antigenicity. However, the long-term durability of GA-fixed cardiovascular xenografts treated with previous anticalcification strategies has remained a challenge because tissue phospholipids, free aldehyde groups of GA, and residual antigenicity contribute to calcification. This study aimed to assess the safety, efficacy, and clinical performance of a bovine pericardial scaffold treated with our novel anticalcification protocols (Periborn) in patients with cardiovascular diseases.

METHODS: Bovine pericardia were decellularized with 0.25% sodium dodecyl sulfate, 0.5% Triton X-100, and treated with a space-filler with polyethylene glycol. These tissues were cross-linked with 0.5% GA in a 75% ethanol +5% octanol organic solvent and treated with glycine for detoxification to produce Periborn. Between July 2015 and April 2022, 451 Periborn patches were implanted in 352 cases for cardiovascular surgeries.

RESULTS: The mean age at the time of surgery was 22.74 ± 20.09 years (13 days-89.5 years), follow-up duration was 4.25 ± 2.56 years (17 days-8.6 years), and no patch-related mortalities were observed. Five patients were reoperated owing to patch-related complications including decreased mobility, erosion, pseudoaneurysm, and calcification, and the overall probability of freedom from Periborn-related reoperation was 99.4% ± 0.4% at 1 year, 98.6% ± 0.7% at 5 years, and 95.4% ± 3.2% at 9 years.

CONCLUSIONS: This retrospective study demonstrates the safety and efficacy of the tissue-engineered Periborn bovine pericardial scaffold for the surgical repair of various cardiovascular diseases. The excellent durability and hemodynamic performance of Periborn make our novel anti-calcification protocol attractive and may require long-term follow-up to confirm durability and further research.

PMID:40213904 | DOI:10.1111/aor.15010